MedTrace Logo

Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients"

NCT05103644 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-11-02

No results posted yet for this study

Summary

Statins, a major class of drugs for treatment of hypercholesterolemia, are widely used due to a notable prevention of cardiovascular disease, and accumulating evidence proposes a promising role of statins in breast cancer

Conditions

Interventions

DRUG

Atorvastatin 80mg

patients received statin experimental group

OTHER

placebo

patients received placebo control group

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Ahmed Hassan shaaban, MD · Beni-Suef University

  • Raghda RS Hussein, PHD · Beni-Suef University

  • Reham shehab El-Nemr, MD · Fayoum University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-30
Primary Completion
2023-12-30
Completion
2024-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05103644 on ClinicalTrials.gov